<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60375">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883635</url>
  </required_header>
  <id_info>
    <org_study_id>46413</org_study_id>
    <nct_id>NCT01883635</nct_id>
  </id_info>
  <brief_title>Exercise Intervention for Cancer Survivors and Caregivers</brief_title>
  <official_title>Dyadic Exercise Intervention for Cancer Survivors and Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see whether exercise can improve the health and well-being of
      cancer survivors.  We also want to know about the health and well being of caregivers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Psychological distress</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A dyadic exercise intervention will result in greater improvements in self reported distress among survivors, caregivers, and in the dyad overall than an individual intervention.  This will be assessed by the Profile of Moods States (POMS) questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Bio-Markers</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A dyadic exercise intervention will result in greater improvements in immune bio-markers associated with stress, (as assessed by serum amyloid A, CRP, cortisol) among survivors and caregivers.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Provision of social support</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A dyadic exercise intervention will result in greater improvements in provision of social support among survivors and caregivers as assessed by the dyadic support questionnaire.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer Survivors and Their Primary Caregivers</condition>
  <arm_group>
    <arm_group_label>Individual Exercise Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and resistance prescription for 6 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dyadic Exercise Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and resistance prescription for 6 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Progressive walking and resistance exercise program</intervention_name>
    <arm_group_label>Individual Exercise Intervention</arm_group_label>
    <arm_group_label>Dyadic Exercise Intervention</arm_group_label>
    <other_name>EXCAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Cancer Survivors:

          -  Have a diagnosis of cancer (any cancer type excluding squamous and basal cell skin
             cancers) and have received surgery, chemotherapy, and/or radiation therapy within the
             last 1-12 months.

          -  Have a functional capacity rating of 70 or greater on the Karnofsky Performance Scale
             or a rating of 1 or 0 on the ECOG scale when assessed by a medical oncologist (or
             physicians designee) following cancer treatments

          -  Have a caregiver willing to participate int he study

          -  Be able to read English

          -  Be 21 years of age or older

          -  Give written informed consent

        Inclusion Criteria for Caregivers:

          -  Be nominated by a cancer survivor

          -  Be able to read English

          -  Be 21 years of age or older

          -  Give written informed consent

        Exclusion Criteria:

          -  have physical limitations (e.g. cardiorespiratory, orthopedic) contraindicating
             participation in a low to moderate intensity home based walking and progressive
             resistance program, as assessed by their medical oncologist, their primary care
             physician, and/or the study medical monitor.

          -  For caregivers, be currently undergoing active treatment for cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Kamen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Kamen, PhD</last_name>
    <phone>585-275-9958</phone>
    <email>charles_kamen@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Murray, MS</last_name>
    <phone>585-276-4638</phone>
    <email>nicole_murray@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Kamen, PhD</last_name>
      <phone>585-275-9958</phone>
      <email>charles_kamen@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Murray, MS</last_name>
      <phone>585-276-4638</phone>
      <email>nicole_murray@urmc.rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chalres Kamen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>June 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
